AR133375A1 - Compuestos novedosos - Google Patents

Compuestos novedosos

Info

Publication number
AR133375A1
AR133375A1 ARP240101971A ARP240101971A AR133375A1 AR 133375 A1 AR133375 A1 AR 133375A1 AR P240101971 A ARP240101971 A AR P240101971A AR P240101971 A ARP240101971 A AR P240101971A AR 133375 A1 AR133375 A1 AR 133375A1
Authority
AR
Argentina
Prior art keywords
novel compounds
compounds
novel
methods
general formula
Prior art date
Application number
ARP240101971A
Other languages
English (en)
Inventor
David Bon
Lea Aurelie Bouche
Wolfgang Guba
Emma Hargrave
Georg Jaeschke
Heather Jennifer Johnston
Stefanie Katharina Mesch
Christian Schnider
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR133375A1 publication Critical patent/AR133375A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos novedosos que tienen la fórmula general (1) en donde X, R¹, R², R³ y n son como se describen en la presente, composición que incluye los compuestos y métodos para usar los compuestos.
ARP240101971A 2023-07-28 2024-07-26 Compuestos novedosos AR133375A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP23188312 2023-07-28

Publications (1)

Publication Number Publication Date
AR133375A1 true AR133375A1 (es) 2025-09-24

Family

ID=87520076

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101971A AR133375A1 (es) 2023-07-28 2024-07-26 Compuestos novedosos

Country Status (6)

Country Link
US (1) US20260193239A1 (es)
EP (1) EP4754096A1 (es)
CN (1) CN121586712A (es)
AR (1) AR133375A1 (es)
TW (1) TW202510869A (es)
WO (1) WO2025026882A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4337652T (lt) 2021-05-12 2025-06-25 F. Hoffmann-La Roche Ag Nlrp3 inhibitoriai
EP4347571B1 (en) * 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
WO2024099993A1 (en) * 2022-11-09 2024-05-16 F. Hoffmann-La Roche Ag Triazinone derivatives as nlrp3 inhibitors

Also Published As

Publication number Publication date
WO2025026882A1 (en) 2025-02-06
CN121586712A (zh) 2026-02-27
EP4754096A1 (en) 2026-06-10
US20260193239A1 (en) 2026-07-09
TW202510869A (zh) 2025-03-16

Similar Documents

Publication Publication Date Title
AR131006A1 (es) Compuestos novedosos
AR131282A1 (es) Compuestos novedosos
AR130984A1 (es) Compuestos novedosos
AR123424A1 (es) Nuevos compuestos heterocíclicos
CL2021001330A1 (es) Nuevos compuestos heterocíclicos
CL2023003154A1 (es) Compuestos heterocíclicos
CO2023016204A2 (es) Inhibidores de nlrp3
AR132377A1 (es) Compuestos novedosos
CL2024004085A1 (es) Compuestos macrocíclicos inhibidores de kras, uso para tratar cáncer.
CL2022001091A1 (es) Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco (divisional de solicitud 202001871).
CO2022002000A2 (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
CL2023002429A1 (es) Derivados novedosos de pirimidin-2-il sulfonamida
AR131278A1 (es) Compuestos novedosos
CL2022000019A1 (es) Nuevos compuestos heterocíclicos
CO2022002336A2 (es) Compuestos heterocíclicos
CO2022003062A2 (es) Compuestos heterocíclicos
AR132456A1 (es) Compuestos novedosos
CR20240203A (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
CO2025003256A2 (es) Derivados novedosos deuterados de pirimidin-2-il sulfonamida
CL2025000126A1 (es) Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina.
CL2025000125A1 (es) Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina.
AR133076A1 (es) Compuestos novedosos
MX2022005912A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria.
AR131633A1 (es) Derivados novedosos de pirimidinil sulfonamida
MX2024000022A (es) Compuestos terapeuticos.